News & Announcements
-
IQ-AI LIMITED SOFTWARE CHOSEN FOR QUANTITATIVE ACCURACY AND AUTOMATION
Sales of Renewal Licenses for Established Clients and a New Installation of IB Clinic at the Eastern Alabama Medical Center.
-
Imaging Biometrics Awarded Patent for No-Contrast MRI Exams
Elm Grove, WI, June 23, 2021 – IQ-AI subsidiary Imaging Biometrics (IB) was awarded a U.S. patent for its artificial intelligence (AI) software technology that eliminates the need for gadolinium-based contrast agents (GBCAs) in medical imaging exams. A zero-dose exam potentially offers remarkable benefits which include a more comfortable patient experience, more productive radiology departments,
-
IQAI commits to phase 1 study for drug candidate in the treatment of Glioblastoma (GBM), a grade IV brain tumor
Elm Grove, WI, April 20, 2021 – IQ-AI, Ltd (publicly traded on the London Stock Exchange as IQAI) will finance a Phase I clinical trial to evaluate the safety and efficacy of Gallium Maltolate (GaM) in the treatment of Glioblastoma Multiforme (GBM). Scheduled to start this summer, the trial will consist of approximately 20 patients
-
LSN Receives FDA Clearance For Virtual Liver Biopsy Software
Birmingham, Ala. Nov. 16, 2020 – AI Metrics, LLC, a medical imaging startup focused on leveraging artificial intelligence to improve patient care, announced today that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the company’s LSN (Liver Surface Nodularity) module. This first FDA clearance represents a significant milestone for AI Metrics, where
-
Imaging Biometrics and Mayo Clinic Enter into Agreement to Develop brain tumor tracking tool
Elm Grove, WI 11/11/2020 – Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI, Ltd, announced today it has launched into a joint venture with Mayo Clinic to develop a brain lesion tracking platform, IB Trax.